That’s a good finding but needs to be watched.
When Raoult’s first publication of results in France was made, he had only 20 cases. That caused people to stand back because those are truly anecdotal numbers.
Raoult continued and published again with 80 cases and that drew more serious reviews.
Zelenko’s numbers are in the hundreds and hundreds from early last week and are likely over a thousand by now.
rhEPO is highly reactive. I remember it’s early clinical trials at Swedish and the Hutch in the 2000s. It’s a wonderful agent for surgeons who can avoid or minimize transfusions.
But it’s very reactive and will interfere with those on heparin,. other anti-hypertensives. So it needs careful attention from doctors administering it. It’s not so reactive that it should be denied as treatment o/w surgeons would avoid it. They don’t.
But it could be a great alternative. We need to wait on numbers but maybe not oo long as it’s been around long enough for many doctors to know how to use it. But I expect such doctors are hospitalists and not outpatient primary care Docs. That could present a difficulty in treating the public.
The thing about HCQ + Zinc is that HCQ has been studied and used since 1955 and Zinc is a nutrient. Compared to rhEPO, these are benign agents.
OTOH, rhEPO may save a life of a severe case in a very elderly patient as described in your link whereas HCQ + Zinc might struggle.